IL279188B2 - Dosage and effect of C5A antagonists with ANCA-associated vasculitis - Google Patents

Dosage and effect of C5A antagonists with ANCA-associated vasculitis

Info

Publication number
IL279188B2
IL279188B2 IL279188A IL27918820A IL279188B2 IL 279188 B2 IL279188 B2 IL 279188B2 IL 279188 A IL279188 A IL 279188A IL 27918820 A IL27918820 A IL 27918820A IL 279188 B2 IL279188 B2 IL 279188B2
Authority
IL
Israel
Prior art keywords
anca
antagonist
dosing
effect
associated vasculitis
Prior art date
Application number
IL279188A
Other languages
English (en)
Hebrew (he)
Other versions
IL279188A (en
IL279188B1 (en
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of IL279188A publication Critical patent/IL279188A/en
Publication of IL279188B1 publication Critical patent/IL279188B1/en
Publication of IL279188B2 publication Critical patent/IL279188B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL279188A 2018-06-07 2019-06-06 Dosage and effect of C5A antagonists with ANCA-associated vasculitis IL279188B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682013P 2018-06-07 2018-06-07
PCT/US2019/035758 WO2019236820A1 (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Publications (3)

Publication Number Publication Date
IL279188A IL279188A (en) 2021-01-31
IL279188B1 IL279188B1 (en) 2025-12-01
IL279188B2 true IL279188B2 (en) 2026-04-01

Family

ID=68764799

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279188A IL279188B2 (en) 2018-06-07 2019-06-06 Dosage and effect of C5A antagonists with ANCA-associated vasculitis

Country Status (15)

Country Link
US (2) US11191756B2 (https=)
EP (1) EP3801519A4 (https=)
JP (2) JP2021527062A (https=)
KR (2) KR20260027358A (https=)
CN (1) CN112423752A (https=)
AU (1) AU2019282327B2 (https=)
BR (1) BR112020024842A2 (https=)
CA (1) CA3102403A1 (https=)
CL (1) CL2020003171A1 (https=)
IL (1) IL279188B2 (https=)
MA (1) MA52808A (https=)
MX (1) MX2020013166A (https=)
SG (1) SG11202011961YA (https=)
WO (1) WO2019236820A1 (https=)
ZA (1) ZA202007615B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
CN114867473A (zh) * 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20080188528A1 (en) 2006-12-22 2008-08-07 Biediger Ronald J Modulators of C3a receptor and methods of use thereof
RU2010138612A (ru) * 2008-02-20 2012-03-27 Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR
RS54998B1 (sr) * 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
WO2016166357A2 (en) 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAIN U, THE C5A RECEPTOR ANTAGONIST PMX205 AMELIORATES EXPERIMENTALLY INDUCED COLITIS ASSOCIATED WITH INCREASED IL-4 AND IL-10, 31 January 2013 (2013-01-31) *
JAYNE DRW ET AL., RANDOMIZED TRIAL OF C5A RECEPTOR INHIBITOR AVACOPAN IN ANCA-ASSOCIATED VASCULITIS, 11 April 2017 (2017-04-11) *
SHI L, ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS: PREVALENCE, TREATMENT, AND OUTCOMES, 27 September 2017 (2017-09-27) *

Also Published As

Publication number Publication date
ZA202007615B (en) 2024-05-30
CA3102403A1 (en) 2019-12-12
MX2020013166A (es) 2021-03-29
JP2021527062A (ja) 2021-10-11
EP3801519A1 (en) 2021-04-14
AU2019282327A1 (en) 2021-01-07
MA52808A (fr) 2021-04-14
CN112423752A (zh) 2021-02-26
US11191756B2 (en) 2021-12-07
CL2020003171A1 (es) 2021-06-04
KR20210018906A (ko) 2021-02-18
AU2019282327B2 (en) 2025-04-24
EP3801519A4 (en) 2022-03-30
SG11202011961YA (en) 2020-12-30
US12350263B2 (en) 2025-07-08
WO2019236820A1 (en) 2019-12-12
US20220296576A1 (en) 2022-09-22
IL279188A (en) 2021-01-31
BR112020024842A2 (pt) 2021-03-02
US20190374524A1 (en) 2019-12-12
KR20260027358A (ko) 2026-02-27
IL279188B1 (en) 2025-12-01
JP2024114706A (ja) 2024-08-23

Similar Documents

Publication Publication Date Title
IL279188A (en) Dose and effect of C5A antagonists with ANCA-associated vasculitis
IL288457A (en) Humanized anti-human CD19 antibodies and methods of use
IL255336A0 (en) Chimeric antigen receptors and methods of using them
ZA201705720B (en) Anti-dll3 chimeric antigen receptors and methods of use
IL255278A0 (en) Anti-ox40 antibodies and methods of using them
SG10201912519VA (en) Chimeric receptors and methods of use thereof
IL248481B (en) Animals containing c5 and c3 of human origin
HUE073235T2 (hu) Anti-HER2 antitestek és alkalmazási eljárások
SG11201707886WA (en) Humanized anti-c1s antibodies and methods of use thereof
IL252929A0 (en) Anti-acth antibodies from humans and their use
IL254951A0 (en) Monoclonal antibodies of influenza of human origin and methods of using them
HUE072829T2 (hu) MON87429 kukoricaesemény és alkalmazási eljárásai
IL256997B (en) Anti-cd154 antibodies and methods of using them
IL274045B1 (en) Prodrugs of dantrolene and methods of using them
PL3179115T3 (pl) Element mocujący z grupami elementów kotwiących o średnicach zewnętrznych odmiennych w różnych grupach
TWM534203U (en) Bubbler water outlet net and bubbler
HK40050407A (en) Dosing and effect of c5a antagonist with anca-associated vasculitis
GB201509977D0 (en) Dispensers and methods of use thereof
GB201720648D0 (en) Aggregate pellets and methods of forming aggregate pellets
TWM488873U (en) Thin and long cookie structure with a plurality of granules